34 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
Act, or PDUFA, guidelines. Under the current PDUFA performance goals, these six- and ten-month review periods are measured from the 60-day filing … the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA’s
8-K
EX-99.1
CCCC
C4 Therapeutics Inc
22 Feb 24
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:15am
goals and execute through and beyond meaningful value inflection points in order to bring new therapeutic options to patients with difficult-to-treat
ARS
4bxkmkgr3
28 Apr 23
Annual report to shareholders
7:03am
PRE 14A
pkd5kqk03ysrux
18 Apr 23
Preliminary proxy
7:59am
8-K
EX-99.1
0s2zomjxa7v7lyiron
11 Aug 21
C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
4:07pm
424B4
61qx8h6kjpta2jaf0
21 Jun 21
Prospectus supplement with pricing info
8:08am